Gilead has a market cap of $90b. Speculation is out there that without a competitor, their yet to be approved HCV combo drugs will be priced at $70,000. A realistic price considering that current standard of care treatment costs are $90,000.
They expect 300,000 patients a year will be treated. That is $21b a year in revenue.
Just imagine $25m BLT having Gilead by the short and curlies.
